Dr. Simon Pedder Becomes President and Chief Executive Officer of Cellectar Biosciences
April 02, 2014 08:00 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., April 2, 2014 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (OTCQX:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of...
Cellectar Biosciences Full-Year 2013 Financial Results and Recent Highlights
March 25, 2014 16:15 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., March 25, 2014 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (OTCQX:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of...
Cellectar Biosciences to Host Conference Call on March 25th to Discuss Full Year 2013 Financial Results and Provide Quarterly Update on Development Progress
March 19, 2014 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., March 19, 2014 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (OTCQX:CLRB), a biopharmaceutical company developing innovative agents for the detection and treatment of cancer,...
Cellectar Announces Initiation of Phase II Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
March 04, 2014 08:00 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., March 4, 2014 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (OTCQX:CLRB) a biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced...
CORRECTING and REPLACING -- Novelos Therapeutics Announces Corporate Name Change to Cellectar Biosciences, Inc.
February 11, 2014 09:57 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Feb. 11, 2014 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Cellectar Biosciences, Inc., formerly known as Novelos Therapeutics. Inc. (OTCQX:NVLT)...
Novelos Therapeutics Announces Corporate Name Change to Cellectar Biosciences, Inc.
February 11, 2014 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Feb. 11, 2014 (GLOBE NEWSWIRE) -- Novelos Therapeutics, Inc. (OTCQX:NVLT), a biopharmaceutical company developing novel agents for the detection and treatment of cancer, announced that,...
Novelos Therapeutics to Present at the 16th Annual BIO CEO & Investor Conference
February 10, 2014 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Feb. 10, 2014 (GLOBE NEWSWIRE) -- Novelos Therapeutics, Inc. (OTCQX:NVLT) a biopharmaceutical company developing novel agents to detect, treat and monitor a broad spectrum of cancers,...
Novelos Therapeutics Announces Closing of $4.0 Million Private Placement
February 07, 2014 07:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Feb. 7, 2014 (GLOBE NEWSWIRE) -- Novelos Therapeutics, Inc. (OTCQX:NVLT) a pharmaceutical company developing novel agents for the treatment and diagnosis of cancer, is pleased to...
Novelos Therapeutics Announces Definitive Agreements to Raise $4.0 million in Private Placement of Convertible Debentures and Warrants
February 06, 2014 07:30 ET
|
Cellectar Biosciences, Inc.
Proceeds Enable Initiation of Phase II Trial of 124I-CLR1404 in Glioma in First Quarter 2014
MADISON, Wis., Feb. 6, 2014 (GLOBE NEWSWIRE) -- Novelos Therapeutics, Inc. (OTCQX:NVLT), a...